Search company, investor...

Glaukos

glaukos.com

Founded Year

1998

Stage

PIPE | IPO

Total Raised

$124M

Market Cap

2.35B

Stock Price

48.33

Revenue

$0000 

About Glaukos

Glaukos (NYSE: GKOS) is an ophthalmic medical technology company focused on the development and commercialization of products and procedures to transform the treatment of glaucoma, one of the leading causes of blindness. Glaukos developed Micro-Invasive Glaucoma Surgery, or MIGS, in order to improve the traditional glaucoma treatment and management paradigm.

Headquarters Location

229 Avenida Fabricante

San Clemente, California, 92672,

United States

949-367-9600

Missing: Glaukos's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Glaukos's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Glaukos

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Glaukos is included in 2 Expert Collections, including Diabetes.

D

Diabetes

1,900 items

M

Medical Devices

295 items

Companies that received PMA from the FDA since 2014. Companies tagged as #FDAPMA

Glaukos Patents

Glaukos has filed 108 patents.

The 3 most popular patent topics include:

  • Diseases of the eye and adnexa
  • Ophthalmology
  • Eye surgery
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/9/2019

12/13/2022

Diseases of the eye and adnexa, Eye surgery, Ophthalmology, Glaucoma, Visual system

Grant

Application Date

5/9/2019

Grant Date

12/13/2022

Title

Related Topics

Diseases of the eye and adnexa, Eye surgery, Ophthalmology, Glaucoma, Visual system

Status

Grant

Latest Glaukos News

VIDEO: Patients intrigued by advanced technology lenses

Jan 19, 2023

Source: Hovanesian JA. What have you learned, Dorothy? Insights from 20+ years of premium implants. Disclosures: Hovanesian reports financial disclosures with 1-800-DOCTORS, Abbott Medical Optics, AcuFocus, Aerie, Alcon, Alicia Surgery Center, Allegro, Allergan, BlephEx, Cloudbreak Therapeutics, Cord LLC, Eyedetec, Glaukos, Guardion Health Sciences, Harvard Eye Associates, Harvard Hearing, Ingenoeye, IOP/Katena, Ivantis, Kala, MDbackline, Novartis, Ocular Therapeutix, Omeros, ReVision Optics, RxSight, Sarentis, Sensimed, Shire, Sight Sciences, TearLab, Tear Film Innovations, TLC Laser Eye Centers, Valeant and Veracity. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS

Glaukos Frequently Asked Questions (FAQ)

  • When was Glaukos founded?

    Glaukos was founded in 1998.

  • Where is Glaukos's headquarters?

    Glaukos's headquarters is located at 229 Avenida Fabricante, San Clemente.

  • What is Glaukos's latest funding round?

    Glaukos's latest funding round is PIPE.

  • How much did Glaukos raise?

    Glaukos raised a total of $124M.

  • Who are the investors of Glaukos?

    Investors of Glaukos include Novo Ventures, Versant Ventures, InterWest Partners, Frazier Healthcare Partners, OrbiMed Advisors and 7 more.

  • Who are Glaukos's competitors?

    Competitors of Glaukos include iSTAR Medical, Implandata Ophthalmic Products, Ambrx, CytImmune Sciences, VentiRx Pharmaceuticals and 13 more.

Compare Glaukos to Competitors

C
Chakshu Research

Led by a team with vast experience in pharmaceuticals, ophthalmology and start-ups, Chakshu Research is committed to develop pharmaceutical treatments for degenerative ocular diseases. The company are developing a self-administered eyedrop to reduce and repair oxidative damage which has been implicated in blinding degenerative diseases. While the company's drug platform is being tested on the company's lead indication, cataract; the company are also in clinical trials for glaucoma and asteroid hyalosis.

A
Ausio Pharmaceuticals

Ausio Pharmaceuticals is a company focused on the clinical development of S-Equol for major medical needs.

A
Amulet Pharmaceuticals

Amulet Pharmaceuticals is a development stage medical device and therapeudics company where patented NORTECH „ technology aims to provide predictable and targeted time release of Nitric Oxide in the body.

C
Cervelo Pharmaceuticals

Cervelo Pharmaceuticals is a semi-virtual clinical development company founded in 2006. The Company is focused on the in-licensing and development of mid stage neurology small molecule drug candidates. It currently has exclusive worldwide rights for all indications to a small molecule, first in class, drug candidate, which has demonstrated a safe and potentially effective capability against neuropathic and inflammatory pain, as well as inflammation.

N
Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

T
TenX Biopharma

TenX is a biopharmaceutical company focused on late stage development and launch of novel cancer products.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.